Related Experiment Video
Updated: Jun 10, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Transcriptome profiling of Canine Parvovirus 2 Nonstructural gene 1(CPV2.NS1) transfected 4T1 mice mammary tumor
Richa Arora1, Waseem Akram Malla2, Arpit Tyagi3
1Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar, India; Department of Veterinary Biochemistry, College of Veterinary and Animal Sciences, Kishanganj, BASU, Patna, India.
Abstract:
Oncolytic viral gene therapy is a directed approach to target cancer cells without affecting healthy cells of the body. Canine parvovirus (CPV2) is an oncolytic virus that precisely targets and destroys neoplastic cells by causing DNA damage, mitochondrial damage, and apoptosis. Non-structural gene 1 (NS1) of CPV, concerned with viral DNA replication is a key mediator of cytotoxicity of CPV and can specifically cause tumor cell lysis. In the present study, by using the transcriptomics approach, we tried to identify molecular pathways and key genes involved in CPV2.NS1 mediated 4T1 mice mammary tumor cell death. We identified necroptosis and mitochondrial damage-mediated apoptosis as major cell death pathways leading to CPV2.NS1 transfected 4T1 cancer cell death. Various DEGs identified in our study play an important role in pathways like the PI3K/AKT pathway, diverse metabolic pathways, MAPK signaling pathway, and FGF signaling pathway, whichare mostly dysregulated in cancerous conditions. Histone variant H2A.X genes, Capn2, and Mapk10/JNK are predicted as key genes that play a role in causing endoplasmic reticulum stress and mitochondrial damage, thereby leading to necroptosis and apoptosis. This study is a preliminary work done to identify key genes and molecular pathways involved in CPV2.NS1 mediated 4T1 cancer cells death which need to be further validated to establish this viral gene as a potent oncolytic agent.
Insights
Canine parvovirus (CPV2) non-structural gene 1 (NS1) effectively targets and destroys 4T1 mouse mammary tumor cells. This oncolytic viral gene therapy induces cell death through necroptosis and mitochondrial damage-mediated apoptosis.
Area of Science:
- Oncolytic virotherapy
- Cancer gene therapy
- Molecular oncology
Background:
- Oncolytic viral gene therapy offers targeted cancer cell destruction.
- Canine parvovirus 2 (CPV2) is an oncolytic virus inducing neoplastic cell death via DNA damage, mitochondrial damage, and apoptosis.
- The CPV non-structural gene 1 (NS1) is crucial for viral DNA replication and mediates CPV's cytotoxicity, enabling tumor cell lysis.
Purpose of the Study:
- To identify molecular pathways and key genes involved in CPV2.NS1-mediated 4T1 mouse mammary tumor cell death using transcriptomics.
- To elucidate the mechanisms underlying CPV2.NS1's oncolytic activity.
Main Methods:
- Transcriptomics approach to analyze gene expression changes in 4T1 cells after CPV2.NS1 transfection.
- Differential gene expression (DEG) analysis to identify key molecular players.
Main Results:
- Necroptosis and mitochondrial damage-mediated apoptosis were identified as primary cell death pathways.
- Key pathways implicated include PI3K/AKT, metabolic pathways, MAPK signaling, and FGF signaling.
- Histone variant H2A.X, Capn2, and Mapk10/JNK were predicted as crucial genes involved in endoplasmic reticulum stress and mitochondrial damage.
Conclusions:
- CPV2.NS1 induces 4T1 cancer cell death through necroptosis and apoptosis.
- The study identified critical molecular pathways and genes contributing to CPV2.NS1's oncolytic effect.
- Further validation is required to establish CPV2.NS1 as a potent oncolytic agent.
